by | Apr 16, 2024 | Publications
Blood Adv. 2024 Apr 23;8(8):1958. doi: 10.1182/bloodadvances.2024013092. NO ABSTRACT PMID:38619855 | DOI:10.1182/bloodadvances.2024013092
by | Apr 16, 2024 | Publications
Blood Adv. 2024 Apr 23;8(8):1991. doi: 10.1182/bloodadvances.2024013036. NO ABSTRACT PMID:38619856 | DOI:10.1182/bloodadvances.2024013036
by | Apr 16, 2024 | Publications
Blood Adv. 2024 Apr 12:bloodadvances.2024012871. doi: 10.1182/bloodadvances.2024012871. Online ahead of print. ABSTRACT Outcomes for relapsed/refractory multiple myeloma (RRMM) patients have dramatically improved following the development and now growing utilization...
by | Apr 15, 2024 | Publications
Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210. Online ahead of print. ABSTRACT BACKGROUND: Conditioning regimens and the choice of immunosuppression have substantial impact on immune reconstitution after allogeneic hematopoietic stem cell transplantation...
by | Apr 15, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Mar 19:S2152-2650(24)00110-1. doi: 10.1016/j.clml.2024.03.003. Online ahead of print. ABSTRACT BACKGROUND: The increasing use of lenalidomide (Len) in first-line (1L) therapy of multiple myeloma (MM) has led to a significant proportion...
by | Apr 15, 2024 | Publications
Br J Haematol. 2024 Apr 14. doi: 10.1111/bjh.19416. Online ahead of print. ABSTRACT The second revision of international staging system (R2-ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent-based induction therapy, autologous...
